[go: up one dir, main page]

PE20131165A1 - 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT - Google Patents

2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Info

Publication number
PE20131165A1
PE20131165A1 PE2013000530A PE2013000530A PE20131165A1 PE 20131165 A1 PE20131165 A1 PE 20131165A1 PE 2013000530 A PE2013000530 A PE 2013000530A PE 2013000530 A PE2013000530 A PE 2013000530A PE 20131165 A1 PE20131165 A1 PE 20131165A1
Authority
PE
Peru
Prior art keywords
fluorine substituted
antiviral treatment
halogen
alkyl
nucleosid
Prior art date
Application number
PE2013000530A
Other languages
Spanish (es)
Inventor
Aesop Chop
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20131165A1 publication Critical patent/PE20131165A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (IV), DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES HALOGENO; R3, R4 Y R5 SON H, HALOGENO, N3, CN, NO2, ENTRE OTROS; n ES 0 A 2; R7 ES H, C(=O)R11, S(O)R11, ENTRE OTROS; R8 ES HALOGENO, N(R11)OR11, N3, NO, ENTRE OTROS; R9 ES H, HALOGENO, NO, NO2, ENTRE OTROS; R11 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), (c), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ARN POLIMERASA DEPENDIENTE DE ARN DEL VIRUS DE LA HEPATITIS CREFERRING TO A HETEROCYCLIC COMPOUND OF FORMULA (IV), WHERE R1 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKYL, AMONG OTHERS; R2 IS HALOGEN; R3, R4 AND R5 ARE H, HALOGEN, N3, CN, NO2, AMONG OTHERS; n IS 0 A 2; R7 IS H, C (= O) R11, S (O) R11, AMONG OTHERS; R8 IS HALOGEN, N (R11) OR11, N3, NO, AMONG OTHERS; R9 IS H, HALOGEN, NO, NO2, AMONG OTHERS; R11 IS H, C1-C8 ALKYL, C2-C8 ALKYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: (a), (b), (c), AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS

PE2013000530A 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT PE20131165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PE20131165A1 true PE20131165A1 (en) 2013-10-14

Family

ID=47748238

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE2013000530A PE20131165A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Country Status (22)

Country Link
EP (1) EP2619206A1 (en)
JP (4) JP2013538230A (en)
KR (1) KR101879887B1 (en)
CN (1) CN103108876A (en)
AP (1) AP3699A (en)
AU (1) AU2011306066B2 (en)
BR (1) BR112013008017A2 (en)
CA (1) CA2807496C (en)
CL (1) CL2013000727A1 (en)
CO (1) CO6680669A2 (en)
CR (1) CR20130172A (en)
EA (1) EA026523B1 (en)
EC (1) ECSP13012560A (en)
IL (1) IL225221A0 (en)
MA (1) MA34593B1 (en)
MX (1) MX2013003179A (en)
NZ (1) NZ608070A (en)
PE (3) PE20230684A1 (en)
PH (1) PH12013500311B1 (en)
SG (1) SG188223A1 (en)
WO (1) WO2012039791A1 (en)
ZA (1) ZA201301042B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment
HRP20130862T1 (en) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SI2595980T1 (en) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
UA116087C2 (en) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Methods for treating hcv
CN104144682A (en) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 Combination formulation of two antiviral compounds
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
TWI678369B (en) 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
CN104230985B (en) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate
TWI740546B (en) 2014-10-29 2021-09-21 美商基利科學股份有限公司 Methods for the preparation of ribosides
ES2892123T3 (en) 2014-12-26 2022-02-02 Univ Emory Antiviral N4-hydroxycytidine derivatives
LT3785717T (en) 2015-09-16 2022-04-11 Gilead Sciences, Inc. TREATMENTS FOR CORONAVIRIDAE INFECTIONS
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
PE20230618A1 (en) 2020-06-24 2023-04-14 Gilead Sciences Inc 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF
DK4204421T3 (en) 2020-08-27 2024-05-27 Gilead Sciences Inc Compounds and methods for treating viral infections
TWI867455B (en) 2022-03-02 2024-12-21 美商基利科學股份有限公司 Compounds and methods for treatment of viral infections
WO2023196975A1 (en) 2022-04-08 2023-10-12 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3256146A1 (en) * 2022-04-25 2025-07-03 Miracure Biotechnology Ltd Nucleoside drug for treating or preventing coronavirus infection, and use thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (en) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1296690A2 (en) 2000-02-18 2003-04-02 Shire Biochem Inc. METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0114837A (en) 2000-10-18 2006-05-09 Pharmasset Ltd modified nucleosides for treatment of viral infections and abnormal cell proliferation
EP1539188B1 (en) * 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
ES2906207T3 (en) * 2003-05-30 2022-04-13 Gilead Pharmasset Llc Modified fluorinated nucleoside analogs
PT3109244T (en) 2004-09-14 2019-06-04 Gilead Pharmasset Llc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (en) * 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ES2390188T3 (en) 2007-01-12 2012-11-07 Biocryst Pharmaceuticals, Inc. Antiviral Nucleoside Analogs
CN101730699A (en) 2007-03-21 2010-06-09 百时美施贵宝公司 Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation
DK2155758T3 (en) 2007-05-10 2012-11-05 Biocryst Pharm Inc TETRAHYDROFURO [3,4-D] DIOXOLAN COMPOUNDS FOR USE IN THE TREATMENT OF VIRUS INFECTIONS AND CANCER
AP3237A (en) 2008-04-23 2015-04-30 Gilead Sciences Inc 1'-Substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
BRPI1013643A2 (en) * 2009-02-10 2016-04-19 Gilead Sciences Inc carba-nucleoside analogues for antiviral treatment
NZ599402A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment

Also Published As

Publication number Publication date
PH12013500311A1 (en) 2013-04-22
WO2012039791A1 (en) 2012-03-29
CL2013000727A1 (en) 2013-08-23
JP2019014726A (en) 2019-01-31
PE20171624A1 (en) 2017-11-02
PE20230684A1 (en) 2023-04-21
CR20130172A (en) 2013-05-29
NZ608070A (en) 2015-11-27
JP2016074732A (en) 2016-05-12
PH12013500311B1 (en) 2017-11-08
EP2619206A1 (en) 2013-07-31
BR112013008017A2 (en) 2016-06-14
CN103108876A (en) 2013-05-15
CA2807496A1 (en) 2012-03-29
JP2013538230A (en) 2013-10-10
MA34593B1 (en) 2013-10-02
AU2011306066B2 (en) 2015-01-29
AP2013006767A0 (en) 2013-03-31
SG188223A1 (en) 2013-04-30
IL225221A0 (en) 2013-06-27
AU2011306066A1 (en) 2013-02-28
KR20130110168A (en) 2013-10-08
ECSP13012560A (en) 2013-06-28
KR101879887B1 (en) 2018-07-18
EA201390141A1 (en) 2013-09-30
ZA201301042B (en) 2014-07-30
CO6680669A2 (en) 2013-05-31
CA2807496C (en) 2019-01-22
JP2017119726A (en) 2017-07-06
MX2013003179A (en) 2013-04-24
EA026523B1 (en) 2017-04-28
JP6475280B2 (en) 2019-02-27
AP3699A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
PE20131165A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120995A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120257A1 (en) CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
CO6331439A2 (en) 1-2 BICYCLES PIRIMIDINONA CARBOXAMIDA AS INHIBITORS OF THE INTEGRESS OF THE HUMAN IMMUNODEFICIENCY VIRUS
PE20140608A1 (en) REPLACED NUCLEOTIDE ANALOGS
CY1118969T1 (en) Pyrimidine-2-amine compounds and their use as JAK kinase inhibitors
PE20171155A1 (en) METHODS AND COMPOUNDS TO TREAT VIRAL PARAMYXOVIRIDAE INFECTIONS
PE20140522A1 (en) DERIVATIVES OF NUCLEOSIDES 2'- SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
EA201590943A1 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
MA37712A2 (en) Macrocyclic inhibitors of flaviviridae virus
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201000100A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS
PE20142456A1 (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks
EA201590384A1 (en) 6-AMINO ACID-HETEROARYDYHYDROPYRIMIDINES FOR THE TREATMENT AND PREVENTION OF INFECTION OF THE HEPATITIS B VIRUS
UY32462A (en) NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT
PH12015501473A1 (en) Novel antiviral agents against hbv infection
AR090760A1 (en) BENZOTIAZOL COMPOUNDS AND THEIR USE AGAINST HIV VIRUS
CR10136A (en) ANTIVIRAL NUCLEOSIDS
PE20091236A1 (en) PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
AR077977A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
PE20211472A1 (en) DERIVATIVES OF 2- (PHENYLOXY OR PHENYLTHIUM) PYRIMIDINE AS HERBICIDES
RU2010140627A (en) Pyrrolidine derivatives
EA201600241A1 (en) SUBSTITUTED (2R, 3R, 5R) -3-HYDROXY- (5-PYRIMIDIN-1-IL) TETRAHYDROFURAN-2-ILMETYL ARIL PHOSPHORAMIDATES
UY31538A1 (en) VIRICA POLYMERASE INHIBITORS
EA201591328A1 (en) HETEROCYCLED SUBSTITUTED TETRICYCLIC COMPOUNDS AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES

Legal Events

Date Code Title Description
FG Grant, registration